Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REX CAMPBELL GARLAND

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1902241813
CMS profile
673872
Location
TEMPLE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$127.77

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $127.77 2

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $127.77 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REX CAMPBELL GARLAND

NPI 1902241813 · CMS profile ID 673872

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

TEMPLE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1902241813?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REX CAMPBELL GARLAND, NPI 1902241813, CMS profile ID 673872. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902241813?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). REX CAMPBELL GARLAND, NPI 1902241813, CMS profile ID 673872. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902241813?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
REX CAMPBELL GARLAND, NPI 1902241813, CMS profile ID 673872, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1902241813?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $127.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $5.1909/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945099125 CMS
GlaxoSmithKline, LLC. $122.5803/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945099123 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $114.32 1
PY2020 $70.31 1
PY2021 $153.45 6
PY2022 $127.77 2
PY2023 $507.82 5
PY2024 $403.03 4
PY2025 $190.17 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $965,516.14 86
PY2024 Principal investigator $293,948.30 30
PY2023 Principal investigator $62,636.64 9
PY2022 Principal investigator $43,443.95 10
PY2021 Principal investigator $129,407.72 30
PY2020 Principal investigator $118,313.60 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $2,310.20 12/27/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1130966858
Principal investigator 1 PFIZER INC. $2,000.00 12/21/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1130966852
Principal investigator 1 PFIZER INC. $22,938.76 12/20/2024 Covered Recipient Teaching Hospital
Scott And White Memorial Hospital
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1130913207
Principal investigator 1 PFIZER INC. $9,099.61 12/18/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1130966865
Principal investigator 1 PFIZER INC. $16,174.93 12/17/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1130967373
Principal investigator 1 PFIZER INC. $17,848.14 12/16/2024 Non-covered Recipient Entity
Baylor Scott and White Health
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1130898413
Principal investigator 1 PFIZER INC. $6,038.20 12/07/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1130967367
Principal investigator 1 PFIZER INC. $26,201.44 11/25/2024 Non-covered Recipient Entity
Baylor Scott and White Health
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1130898081
Principal investigator 1 PFIZER INC. $23,797.52 11/25/2024 Non-covered Recipient Entity
Baylor Scott and White Health
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1130898085
Principal investigator 1 PFIZER INC. $2,000.00 11/25/2024 Non-covered Recipient Entity
Baylor Scott and White Health
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1130936028
Principal investigator 1 PFIZER INC. $6,658.30 11/21/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1130988509
Principal investigator 1 PFIZER INC. $7,610.85 11/06/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1130988504
Principal investigator 1 PFIZER INC. $3,127.95 10/25/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1130993164
Principal investigator 1 PFIZER INC. $22,154.10 10/16/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1130993158
Principal investigator 1 PFIZER INC. $22,957.50 10/05/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1130993330
Principal investigator 1 PFIZER INC. $5,842.80 10/02/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1130993171
Principal investigator 1 PFIZER INC. $12,965.55 10/01/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1130993336
Principal investigator 1 PFIZER INC. $750.00 09/07/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1131018609
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,825.00 09/06/2024 Non-covered Recipient Entity
Baylor Scott And White Research Institute
Phase III RRMM: 480Kd vs Kd (SUCCESSOR 2) - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR R No dispute reported 06/30/2026 1123476132
Principal investigator 1 PFIZER INC. $1,975.00 07/04/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1131043553
Principal investigator 1 PFIZER INC. $1,975.00 06/05/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1131067175
Principal investigator 1 Celgene Corporation $8,000.00 06/03/2024 Non-covered Recipient Entity
Baylor Scott And White Health Research Institute
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting No dispute reported 06/30/2026 1120433136
Principal investigator 1 ABBVIE INC. $136.50 05/29/2024 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE DBA BAYLOR SCOTT & WHITE RESEARCH INSTITUTE
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naive Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy No dispute reported 06/30/2026 1100719790
Principal investigator 1 PFIZER INC. $11,750.00 05/15/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1131075004
Principal investigator 1 PFIZER INC. $2,257.20 04/04/2024 Non-covered Recipient Entity
Baylor Scott White Medical Center Temple
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1130916058
Principal investigator 1 ABBVIE INC. $1,976.00 03/14/2024 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naive Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy No dispute reported 06/30/2026 1100708471
Principal investigator 1 ABBVIE INC. $3,573.00 02/20/2024 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naive Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy No dispute reported 06/30/2026 1100704206
Principal investigator 1 ABBVIE INC. $15,208.70 02/08/2024 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naive Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy No dispute reported 06/30/2026 1100703430
Principal investigator 1 PFIZER INC. $28,288.00 02/06/2024 Non-covered Recipient Entity
Baylor Scott White Research Institute
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1131097812
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,508.05 01/25/2024 Covered Recipient Teaching Hospital
Scott And White Memorial Hospital
Phase III RRMM: 480Kd vs Kd (SUCCESSOR 2) - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR R No dispute reported 06/30/2026 1123474169